Small molecule NOX inhibitors for diabetic neuropathy
This article was originally published in Start Up
Genkyotex SA, named after Geneva, Kyoto and Texas, the locations of three of the academic founders, is developing small molecules that specifically inhibit NOX enzymes. Its lead product is a selective and orally available NOX1/4 inhibitor and is a first-in-class molecule. The initial target for this product is diabetic nephropathy, but the company believes it has potential in a range of other disorders in areas of unmet medical need, including in atherosclerosis, ophthalmological diseases involving angiogenesis such as retinopathy and wet age-related macular degeneration, and fibrosis. The agent has orphan drug status in the EU and the US for the treatment of idiopathic pulmonary fibrosis.
You may also be interested in...
GenKyoTex's first-in-class NOX inhibitors and PsiOxus's oncolytic viruses attract funding from European VCs to cross "death valley."
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways